NGM Biopharmaceuticals, Inc.

NGM · NASDAQ
Analyze with AI
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Activities
Net Income-$142-$163-$120-$102
Dep. & Amort.$2$4$6$7
Deferred Tax$5$0$4-$0
Stock-Based Comp.$29$32$26$16
Change in WC-$18-$21$4-$4
Other Non-Cash-$7$3$7$1
Operating Cash Flow-$132-$144-$73-$83
Investing Activities
PP&E Inv.-$1-$2-$2-$2
Net Acquisitions$0-$16$70$49
Inv. Purchases-$105-$273-$293-$178
Inv. Sales/Matur.$221$289$224$129
Other Inv. Act.$0$16-$70-$49
Investing Cash Flow$114$14-$72-$51
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$2$3$0$0
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$2$54$150$36
Financing Cash Flow$2$54$150$36
Forex Effect$1$0$0$0
Net Chg. in Cash-$15-$76$5-$99
Supplemental Information
Beg. Cash$73$153$149$247
End Cash$59$77$153$149
Free Cash Flow-$133-$146-$75-$85
NGM Biopharmaceuticals, Inc. (NGM) Financial Statements & Key Stats | AlphaPilot